iShares 7-10 Year Treasury Bond ETF vs Vaxcyte Inc. Common Stock — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $90.06 (market cap $41.26B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 3.9× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| IEF | PCVX | |
|---|---|---|
Market Cap | $41.26B | $10.51B |
Volume | 12,778,487 | 2,644,694 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $73.82 |
52-Week Low | $88.92 | $40.32 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.71, up 0.31% with a bearish technical signal from moving averages and oscillators. The ETF shows flat support/resistance around $89-90. Recent dividend payments of $0.31-$0.33 provide income, but financial ratios are unavailable. Market sentiment reflects Treasury volatility amid rising yields and inflation concerns.
Outlook remains cautious due to persistent bond market pressures and macroeconomic uncertainty. Opportunities exist for income-focused investors via dividends, but risks include prolonged yield increases and geopolitical factors affecting fixed income. Monitor Federal Reserve policy shifts for directional cues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →